Xtant Medical (NYSEAMERICAN:XTNT) Stock Price Crosses Above 200 Day Moving Average of $0.00

Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.60. Xtant Medical shares last traded at $0.57, with a volume of 13,702 shares traded.

Xtant Medical Price Performance

The company has a market cap of $74.62 million, a PE ratio of -57.26 and a beta of 0.36. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.44 and a quick ratio of 1.01.

Xtant Medical (NYSEAMERICAN:XTNT) last posted its quarterly earnings results on Thursday, August 8th. The medical device company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The company had revenue of $29.94 million for the quarter. Xtant Medical had a negative net margin of 3.00% and a negative return on equity of 6.71%.

Institutional Investors Weigh In On Xtant Medical

An institutional investor recently raised its position in Xtant Medical stock. Vanguard Group Inc. lifted its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 3.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,548,312 shares of the medical device company’s stock after acquiring an additional 48,319 shares during the period. Vanguard Group Inc. owned approximately 1.19% of Xtant Medical worth $1,812,000 at the end of the most recent reporting period. 69.33% of the stock is owned by institutional investors.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.